Related Experiment Videos
Antisense oligonucleotides as therapeutics for malignant diseases
1Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD 20852, USA.
Seminars in Oncology
|April 1, 1997
Summary
Antisense oligonucleotides offer a promising therapeutic strategy by targeting specific mRNA to inhibit protein synthesis. Despite challenges in development, ongoing clinical trials are paving the way for next-generation antisense agents in cancer treatment.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- Advances in understanding neoplasia biology and gene sequencing enable the development of targeted cancer therapies.
- Antisense oligonucleotides (ASOs) are investigated as a therapeutic modality leveraging molecular sequencing to inhibit gene function.
Purpose of the Study:
- To explore the potential of antisense oligonucleotides as a therapeutic approach for malignant and non-malignant diseases.
- To identify and discuss the challenges and future directions in the preclinical development of ASOs.
Main Methods:
- ASO approach utilizes short oligonucleotides designed to hybridize with target messenger RNA (mRNA) via Watson-Crick base pairing.
- This hybridization forms an oligonucleotide: RNA heteroduplex, leading to mRNA inactivation and inhibition of protein synthesis.
- Review of preclinical development challenges and clinical trial progress in oncology.
Main Results:
- The antisense approach theoretically offers broad applicability to any gene product for disease treatment.
- Significant preclinical challenges identified include stability, cellular uptake, target selection, and manufacturing costs.
- Early clinical trials in oncology targeting genes like p53 and bcl-2 are providing valuable experience.
Conclusions:
- While theoretically attractive, the practical application of ASOs faces considerable preclinical hurdles.
- Pharmacokinetics and toxicology of current ASO analogues appear relatively non-sequence-specific.
- Future progress in antisense therapeutics depends on resolving these preclinical challenges and developing next-generation molecules.